Immunoassay for Colistin Monitoring in Critically Ill Patients Receiving Colistin Methanesulfonate Therapy
Pharmaceuticals · 2026-06-01 · 19 (6) · 880
DOI: 10.3390/ph19060880 ↗At a glance
Journal article in Pharmaceuticals, published online on 2026-06-01. Written by Yury A Surovoy and 5 co-authors. Institution: Department of Critical Care, University College of London Hospital, London NW1 2BU, UK. 45 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Background/Objectives: Colistin (COL), administered as a prodrug colistimethate sodium (CMS), is commonly used to treat infections caused by multidrug-resistant Gram-negative bacteria in critically ill patients. Given high CMS instability, very complex and variable pharmacokinetics (PK) and high incidence of toxicity, therapeutic drug monitoring (TDM) of active COL might play an important role. This study aimed to develop and validate an accessible immunoassay-based approach for COL monitoring in human serum.
Methods
A direct competitive enzyme-linked immunosorbent assay (dcELISA) was developed using polyclonal (pAb) anti-polymyxin antibody alongside a polymyxin B–horseradish peroxidase conjugate. CMS conversion to COL along with serum deproteinization was achieved using 5% trichloroacetic acid (TCA) treatment at 37 °C. Assay accuracy and precision were assessed by spike-and-recovery experiments in healthy volunteer serum. The assay was applied to serum samples from critically ill patients with burns or pneumonia receiving CMS therapy. The reliability of the measurements was confirmed by parallel dcELISA based on a reference monoclonal antibody (mAb) against fragmented polymyxin molecule.
Results
Both ELISA formats demonstrated high sensitivity, with limits of detection of 0.053 ng/mL (pAb) and 0.047 ng/mL (mAb). TCA treatment achieved maximal CMS hydrolysis under tested conditions within one hour. Clinical sample analysis showed excellent agreement between the two assays (R2 = 0.996), with Bland–Altman analysis revealing a minimal bias of 3.7%. Exploratory PK analysis in burn patients demonstrated increased total drug volume of distribution (45.7–64.9 L) and clearance (8.3–16.3 L/h).
Conclusions
This is the first report of ELISA for COL TDM in critically ill patients. The method offers acceptable analytical performance and practical simplicity, with potential to broaden TDM access beyond specialist centers.
Subjects
Author keywords
Authors and institutions
- Department of Critical Care, University College of London Hospital, London NW1 2BU, UK.
- Faculty of Science and Technology, Middlesex University, London NW4 4BT, UK.
- Department of Immunology, I. Mechnikov Research Institute for Vaccines and Sera, Moscow 105064, Russia.
- Faculty of Medicine, M.V. Lomonosov Moscow State University, Moscow 119991, Russia.
- Federal Center for Treatment and Rehabilitation, Ministry of Health, Moscow 125367, Russia.
- College of Veterinary Medicine, China Agricultural University, Beijing 100193, China.
ORCID profiles: Inna A Galvidis, Akmal I Alimov, Zhanhui Wang, Artem O Melekhin, Maksim A Burkin
Cite
APA
Surovoy, Y. A., Galvidis, I. A., Alimov, A. I., Wang, Z., Melekhin, A. O., & Burkin, M. A. (2026). Immunoassay for Colistin Monitoring in Critically Ill Patients Receiving Colistin Methanesulfonate Therapy. Pharmaceuticals, 19(6), 880. https://doi.org/10.3390/ph19060880
Vancouver
Surovoy YA, Galvidis IA, Alimov AI, Wang Z, Melekhin AO, Burkin MA. Immunoassay for Colistin Monitoring in Critically Ill Patients Receiving Colistin Methanesulfonate Therapy. Pharmaceuticals. 2026;19(6):880. doi:10.3390/ph19060880
BibTeX
@article{Surovoy2026,
author = {Surovoy, Yury A and Galvidis, Inna A and Alimov, Akmal I and Wang, Zhanhui and Melekhin, Artem O and Burkin, Maksim A},
title = {Immunoassay for Colistin Monitoring in Critically Ill Patients Receiving Colistin Methanesulfonate Therapy},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {6},
pages = {880},
doi = {10.3390/ph19060880}
}
EUVIMED